Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kineta Inc KANT

Kineta, Inc. is a clinical-stage biotechnology company. The Company has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance: immunosuppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of immunotherapies includes KVA12123, which is a... see more

Recent & Breaking News (OTCPK:KANT)

Proteostasis Announces Presentations at the 41st European Cystic Fibrosis Society Conference

PR Newswire June 1, 2018

Proteostasis Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference

PR Newswire May 31, 2018

Proteostasis Announces Formation of Independent Steering Committee of Leading Experts to Advise on the Global Phase 3 Clinical Development Program for PTI-428 in Cystic Fibrosis

PR Newswire May 8, 2018

Lifshitz & Miller LLP Announces Investigation of Acadia Pharmaceuticals Inc., Allegiant Travel Company, Camping World Holdings, Inc., Finish Line, Inc., Myriad Genetics, Inc., Proteostasis Therapeutics, Inc., Under Armour, Inc. and United Community Bancor

PR Newswire April 24, 2018

Proteostasis Receives Endorsement from the Cystic Fibrosis Foundation's Therapeutic Development Network for the Study of the Company's Amplifier, PTI-428, in CF Subjects on Background Symdeko™ Therapy

PR Newswire April 17, 2018

A Peek Into The Markets: U.S. Stock Futures Signal Higher Start On Wall Street

Benzinga.com  April 9, 2018

5 Stocks To Watch For April 9, 2018

Benzinga.com  April 9, 2018

36 Biggest Movers From Yesterday

Benzinga.com  April 5, 2018

30 Stocks Moving In Wednesday's Mid-Day Session

Benzinga.com  April 4, 2018

18 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com  April 4, 2018

Proteostasis Therapeutics Receives FDA Fast Track Designation for Triple Combination Program in Patients with Cystic Fibrosis

PR Newswire April 4, 2018

PTI INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Proteostasis Therapeutics, Inc. Investors

Business Wire April 3, 2018

PROTEOSTASIS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Proteostasis Therapeutics, Inc. To Contact The Firm

PR Newswire March 22, 2018

Glancy Prongay & Murray LLP Continues Investigation on Behalf of Proteostasis Therapeutics, Inc. Investors (PTI)

Business Wire March 22, 2018

Glancy Prongay & Murray LLP Announces Investigation on Behalf of Proteostasis Therapeutics, Inc. Investors (PTI)

Business Wire March 21, 2018

Bragar Eagel & Squire, P.C. is Investigating Proteostasis Therapeutics, Inc. (PTI) on Behalf of Stockholders and Encourages Investors to Contact the Firm

Business Wire March 21, 2018

Scott+Scott Attorneys at Law LLP Announces Investigation into Proteostasis Therapeutics, Inc. (PTI)

PR Newswire March 21, 2018

7 Biotech Movers To Watch Today: Prothena, Proteostasis, Global Blood Therapeutics And More

Benzinga.com  March 21, 2018

20 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com  March 21, 2018

Benzinga Pro's 6 Stocks To Watch Today

Benzinga.com  March 21, 2018